+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT compared to a placebo in treating psychosis linked to Alzheimers Disease. This Phase 3 outpatient study lasts 38 weeks and aims to prevent relapse of psychosis symptoms in affected adults aged 55 to 90. The trial also looks at how long participants stay on treatment without relapse or stopping for any reason, along with monitoring safety and tolerability. Participants are randomly assigned to receive either KarXT capsules in varying doses or placebo capsules. The treatment is administered three times a day during the study period. This double-blind trial ensures neither participants nor researchers know which treatment is given. The study is conducted at multiple centers and includes a placebo control to compare outcomes. Throughout the 38 weeks, participants will attend regular visits for assessments including cognitive tests like the Mini-Mental State Examination, evaluations of psychosis severity, caregiver-reported measures, and safety monitoring such as laboratory tests, vital signs, and adverse event tracking. Researchers will measure the time to relapse and treatment discontinuation, along with side effects and other health indicators. The study is sponsored by Karuna Therapeutics, a Bristol Myers Squibb company.

Age: 55Years - 90YearsAll GendersPhase 3
129 locations
R

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of ITI-1284, a sublingual drug, compared with placebo in treating psychosis associated with Alzheimers disease. This Phase 2, multicenter, randomized, double-blind, placebo-controlled study involves adults aged 55 and older diagnosed with Alzheimers disease and psychosis. The study aims to improve understanding of how ITI-1284 may affect psychotic symptoms in this population. Participants will receive either ITI-1284 tablets at doses of 10 mg or 20 mg or matching placebo tablets, taken once daily by sublingual administration. The study uses a flexible-dose design and follows a parallel-group model with random assignment to the drug or placebo groups. Treatment and assessments are conducted over the study period, with primary measurement of psychosis symptoms at Week 6. Throughout the trial, participants will be monitored regularly for symptom changes using the BEHAVE-AD psychosis subscale and the Clinical Global Impression-Severity score. Cognitive function will be evaluated using the Mini-Mental State Examination. Safety and tolerability will be assessed continuously, and a designated caregiver will support participants. The total study duration extends through to December 2028, with primary outcomes assessed at 6 weeks.

Age: 55Years +All GendersPhase 2
71 locations
M

Actively Recruiting

Researchers are conducting a master protocol consisting of three independent, multicenter, randomized, double-blind, placebo-controlled studies to evaluate ACP-204 in adults with Alzheimers Disease Psychosis ADP. The purpose is to assess the efficacy and safety of two doses of ACP-204 compared to placebo. The studies include a Phase 2 dose-response trial followed by two Phase 3 confirmatory trials, each analyzed separately. The research addresses the treatment of psychosis symptoms in adults aged 55 to 95 years with confirmed Alzheimers disease and psychosis. Participants receive either ACP-204 at 30 mg or 60 mg doses or a matching placebo once daily, approximately at the same time each day, with or without food. Each substudy includes a screening period lasting up to 49 days, a 6-week double-blind treatment period, and a 30-day safety follow-up for those not entering an open-label extension. Vital status follow-up is also conducted for participants who end the study early. During the study, participants undergo assessments including the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales SAPS-HD and the Clinical Global Impression-Severity in the ADP context CGI-S-ADP. Study visits involve evaluation with a designated caregiver or study partner. Safety monitoring and vital status checks continue after treatment, with the total participation duration including screening, treatment, and follow-up periods.

Age: 55Years - 95YearsAll GendersPhase 2Phase 3
154 locations
D

Actively Recruiting

Researchers are conducting a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ACP-204 in adults with Lewy Body Dementia Psychosis LBDP. This study aims to understand how ACP-204 affects psychosis symptoms in participants aged 55 to under 85 years. It compares two doses of ACP-204 against a placebo over a six-week period. Participants are assigned to one of three groups receiving 30 mg of ACP-204 once daily, 60 mg of ACP-204 once daily, or a placebo once daily. The medication is provided as a capsule taken orally. The study lasts six weeks, during which participants take their assigned treatment daily while remaining unaware of their group assignment. Throughout the trial, participants will be monitored regularly to assess changes in their psychosis symptoms using the SAPS-LBDP total score at week 6. Safety and tolerability will also be evaluated. The study includes screening for eligibility, regular visits during treatment, and assessments to track symptom changes and any side effects over the six-week treatment period.

Age: 55Years - 84YearsAll GendersPhase 2
62 locations
W

Actively Recruiting

Researchers are conducting a 52-week, open-label extension study to evaluate ACP-204 in adults with Lewy Body Dementia Psychosis LBDP. This Phase 3 trial aims to assess long-term treatment effects and safety in participants who have previously completed an antecedent ACP-204 study. The study is sponsored by ACADIA Pharmaceuticals Inc. and focuses on adults aged 55 to 84 years. Participants will receive ACP-204 capsules taken orally once daily, starting at 30 mg. The dose may be adjusted during the trial, allowing for increases to 60 mg or reductions back to 30 mg depending on treatment response. The study design includes a single treatment group with no placebo or comparison groups, and treatment is provided openly without masking. Throughout the 52 weeks, participants and their study partners or caregivers will attend all study visits and complete assessments under supervision. Researchers will monitor for treatment-emergent adverse events as the primary outcome. Participants must be able to provide informed consent or assent with consent from a legally authorized representative. Safety and efficacy evaluations will be conducted regularly to ensure participant well-being during the study period.

Age: 55Years - 84YearsAll GendersPhase 3
36 locations
R

Actively Recruiting

Researchers are evaluating lumateperone as an additional treatment for adults aged 18 to 65 years with major depressive disorder MDD who have not responded adequately to current antidepressant treatments. This phase 3, multicenter study is randomized, double-blind, and placebo-controlled, aiming to assess the efficacy and safety of lumateperone in this population. The study includes patients with moderate to severe depression diagnosed according to DSM-5 criteria, including those with psychotic features. Participants will be randomly assigned to receive either lumateperone 42 mg capsules or matching placebo capsules once daily for six weeks during the double-blind treatment period. The study consists of three distinct periods an initial screening lasting up to two weeks to determine eligibility, the six-week treatment phase with daily medication, and a one-week safety follow-up after the last dose to monitor any adverse effects. During the study, participants will undergo assessments including depression rating scales such as the Montgomery-Asberg Depression Rating Scale MADRS and Clinical Global Impression Scale-Severity. Safety evaluations will be conducted throughout, including a follow-up visit about one week after treatment ends. The total participation time may last up to nine weeks, encompassing screening, treatment, and safety monitoring.

Age: 18Years - 65YearsAll GendersPhase 3
69 locations